Accessibility Log In Help Join The Motley Fool

Patrick Bafuma

TMFfuma102

Recent Articles by Patrick Bafuma

GettyImages-639817322

Aug 4, 2022 by Patrick Bafuma

These 3 Companies Are Taking on Monkeypox

A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.

GettyImages-1365436662

Aug 3, 2022 by Patrick Bafuma

Famed "Big Short" Investor Loves This Multibillion-Dollar Company -- Should You?

Will Bristol-Myers Squibbs' pipeline and newly approved drugs overcome its expiring patents?

GettyImages-639817322

Jun 19, 2022 by Patrick Bafuma, George Budwell, and Taylor Carmichael

Buy the Dip on These 3 Healthcare Stocks

Here's why our roundtable likes Vir Biotechnology, OrthoPediatrics, and Vertex Pharmaceuticals.

GettyImages-981733948

May 2, 2022 by Patrick Bafuma

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

CEO Vas Narasimhan is seeking acquisitions under $2 billion.

Apr 29, 2022 by Patrick Bafuma

These Charts Explain Why I'm Holding This Healthcare Company

Transplants are in high demand; this company is making the process of getting one smoother.

Apr 28, 2022 by Patrick Bafuma

2 Healthcare Stocks That Could Go Parabolic

These two companies are poised for a comeback.

GettyImages-826300274

Apr 28, 2022 by Patrick Bafuma

This Chart Is Why I'm Not Worried About Guardant Health

The leading innovator in the liquid biopsy space has huge addressable markets ahead of it.

GettyImages-1324724366

Apr 27, 2022 by Patrick Bafuma

Why I'm Over the Moon for This Healthcare Stock -- In One Chart

This company helps keep patients at home with dialysis treatments.

GettyImages-1206365629

Apr 26, 2022 by Patrick Bafuma

Things Just Got Worse for Biogen

The company just withdrew its Aduhelm regulatory submission in the EU.

GettyImages-639817322

Apr 20, 2022 by Patrick Bafuma

Missed Intuitive Surgical? Buy This Stock Instead

Much as Intuitive Surgical redefined the surgical field, this company is updating how abnormal heart rhythms are diagnosed.

Apr 20, 2022 by Patrick Bafuma

This Chart Is Why I'm Holding This Stock for the Next Decade

This biotech's products are a must-have for scientists.

Apr 15, 2022 by Patrick Bafuma

2 Medtech Stocks You Can Buy and Hold for the Next Decade

These two companies are leading the charge for improved patient outcomes.

GettyImages-1251894563

Apr 11, 2022 by Patrick Bafuma

2 Under-the-Radar Biotech Stocks to Buy in 2022

Both companies have catalysts for explosive growth this year.

GettyImages-826300274

Apr 8, 2022 by Patrick Bafuma

2 Top Biotech Stocks to Buy in April

These shares are down significantly from all-time highs, but the businesses have plenty of room for growth.

Apr 7, 2022 by Patrick Bafuma

2 Top Biotech Stocks to Buy for the Long Haul

Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.

GettyImages-1284611505

Apr 6, 2022 by Patrick Bafuma

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

These companies have a history of creating shareholder value -- and still have plenty of room for growth.

GettyImages-826300274

Apr 6, 2022 by Patrick Bafuma

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.

Apr 2, 2022 by Patrick Bafuma

Customers Love These 3 Healthcare Companies

Net Promoter Scores can provide insights into customer satisfaction, and possibly lead to market-beating returns.

GettyImages-875110736

Dec 18, 2021 by Patrick Bafuma

3 Last-Minute Healthcare Stocking Stuffers

Here are three stocks sure to pique the interest of that special someone.

GettyImages-826300274

Nov 24, 2021 by Patrick Bafuma and Alex Carchidi

10x Genomics Stock: Bull vs. Bear

After a hot start, the stock has recently lagged the market. Is now a good time to buy?

HOW THE MOTLEY FOOL CAN HELP YOU

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

515%

S&P 500 Returns

133%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services